Synopsis

Source of validity: Scientific
Rating (out of 5): 4

LL12-myoviridae refers to a specific bacteriophage (phage) within the Myoviridae family that targets Staphylococcus aureus, the bacterium responsible for many staph infections. The use of bacteriophages to treat bacterial infections, known as phage therapy, has gained renewed scientific attention, especially in the context of increasing antibiotic resistance. Studies have demonstrated that LL12-myoviridae phages can effectively lyse S. aureus strains, including methicillin-resistant S. aureus (MRSA), in both laboratory and preclinical animal models. Several in vitro studies have confirmed the ability of this phage to reduce bacterial load, and animal model research has shown positive outcomes in treating systemic and localized staph infections.

While human clinical trials using LL12-myoviridae specifically are limited, the broader category of S. aureus-targeting myoviridae phages has been explored in compassionate use cases and early-stage clinical studies with encouraging results. These findings indicate that phage therapy could serve as an adjunct or alternative to antibiotics, particularly in cases where conventional treatments fail or resistance is present. Regulatory and standardization hurdles remain, but the accumulating scientific evidence supports the use of LL12-myoviridae phage as a promising candidate for staph infection treatment, justifying a high evidence rating. Ongoing and future clinical studies will be crucial in fully establishing its safety, efficacy, and best practices for therapeutic use.

More about LL12-myoviridae
More about Staph Infections

Other ingredients used for Staph Infections

Other health conditions supported by LL12-myoviridae

Products containing LL12-myoviridae

Designs For Health Probiophage DF™